Our Advisory Board - andersen cascade impactor – laboratory automation – aci automation

Dr. Richard Dalby is a Dean’s Distinguished Educator, Professor of Pharmaceutical Sciences, as well as the Associate Dean for Academic Affairs at the University of Maryland School of Pharmacy. He is a Fellow of the American Association of Pharmaceutical Scientists.

He has published more than 50 peer reviewed papers and approximately 130 abstracts related to aerosol technology, authored several book chapters, and spoken at many national and international meetings. He is an inventor on three patents concerned with novel MDI formulations, a reviewer for many international journals and a frequently sought after industrial and FDA consultant.

Dr. Dalby is the co-organizer, publication coordinator, editor and Exhibition moderator at the Respiratory Drug Delivery (RDD) Symposium, which is the world’s premier pharmaceutical aerosol meeting attended by researchers, executives and regulatory personnel. The resulting proceeding exceeding 1000 pages are the most up-to-date reference on advances associated with medical aerosol drug delivery.

Richard's aerosol research, which encompasses novel pulmonary and nasal formulation development, device design and product testing, is founded on his Ph.D. work on sustained release metered dose inhalers, and industrial experience as a Formulation Scientist with Fisons (now Sanofi Aventis).

He has a Ph.D. in Pharmaceutical Sciences from the University of Kentucky (1988) (supervised by Dr. Peter R. Byron).

Dr.John Hart has been involved in leading the development of respiratory drug delivery systems for 25 years. He was the COO of Meridica, which developed a hardware-based inhalation system and when Meridica was acquired by Pfizer, he joined them as a Sr. Director. Prior to that he was Sr. Director in Schering-Plough in Inhalation Drug development and led the development of Schering’s dry-powder inhaler. John has held the position of World-Wide Director of Product Development for Rhone-Poulenc Rorer, involving most dosage forms, and in various positions in Fisons Pharmaceuticals. John was the Chairman of the International Pharmaceutical Consortium for Toxicology Testing of HFA 227 from 1990 to 2001.

Dr.Pravin Soni is a senior consultant and founder of PharmaCRO, LLC (www.pharmcro.com), with broad experience in development, manufacture and registration of novel drug, device, and combination medical products, emphasizing value creation through intellectual property development.

As VP Product R&D at Alexza Pharmaceuticals he led the development of a novel inhalable drug delivery system, the Staccato inhaler, for systemic drug delivery via the deep lung. Five different products based on Staccato technology were developed for the treatment of migraine, panic attack, breakthrough pain, insomnia and agitation under Dr. Soni’s direction, and currently these products are in various stages of clinical evaluation. Prior to Alexza, Dr. Soni was at Cygnus Inc where he led the development of the first commercial non-invasive, automatic and continuous blood glucose monitoring system, the GlucoWatch Biographer. At Cygnus he also led the development of a 7-day contraceptive transdermal system that was marketed by Johnson & Johnson as Evra.

Dr. Soni is co-inventor on fifty seven (57) US and foreign patents, and has co-authored nineteen (19) publications/poster presentations. He holds a Ph.D .in Macromolecular Science and Engineering from Case Western Reserve University.

Dr. Rod Woods has 30 years of analytical, quality and process experience in the Chemical and Pharmaceutical industries. Currently Director of Process Analytical Technology at Mannkind Corporation. Dr. Woods has in the past been senior management of Quality Control , Analytical Development, Quality Assurance and Chemical Technology for Mannkind. Prior to Mankind had management positions in Cambrex and Cyanamid . Dr. Woods has a Ph.D. in Analytical Chemistry from Seton Hall University.